Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Neurotrophic Keratitis > Amniotic membrane improves severe autoimmune-related KCS and NK outcomes
  • Neurotrophic Keratitis

Amniotic membrane improves severe autoimmune-related KCS and NK outcomes

Ophthalmology 360

A case report presented at the Association of Cataract and Refractive Surgery (ASCRS) Annual Meeting highlights the successful management of severe keratoconjunctivitis sicca (KCS) and neurotrophic keratopathy (NK) secondary to autoimmune disease using cryopreserved amniotic membrane (CAM) alongside systemic and topical therapies.

The report describes a 32-year-old woman with a history of lupus and common variable immunodeficiency who presented with advanced ocular surface disease, including 4+ superficial punctate keratitis, negligible tear film, significant conjunctival injection, and reduced corneal sensation in both eyes. Visual acuity was 20/100 in the right eye and 20/400 in the left eye at presentation.

Initial treatment included artificial tears, cyclosporine, topical steroids, immunoglobulin therapy, and 2 CAM applications per eye. After 5 weeks, the patient showed partial improvement, with reduced injection and visual acuity improving to 20/70 in both eyes, though tear film remained minimal and staining persisted.

Additional treatment in the left eye with 2 more CAM applications and a 72-hour collagen shield over 4 weeks led to marked improvement, with no injection, minimal staining, improved TBUT and corneal sensation, and visual acuity of 20/20 in the right eye and 20/30 in the left eye.

Reference

Bauza A, et al. Management of Severe Keratoconjunctivitis Sicca and Neurotrophic Keratopathy in a Patient with Lupus and Common Variable Immunodeficiency. Poster presented at: ASCRS Annual Meeting; April 10–13, Washington, DC.

Share

Related Content

  • Neurotrophic Keratitis

Shelf-stable amniotic membrane improved outcomes in early-stage neurotrophic keratopathy

  • Glaucoma

Review finds low adverse event rates for glaucoma stents

  • Retina

Switching to aflibercept 8 mg extends treatment intervals in suboptimal nARMD responders

  • Conference Roundup

Cryopreserved amniotic membrane significantly improves ocular surface integrity in patients with severe keratoconjunctivitis sicca and neurotrophic keratopathy

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

  • Conference Roundup

Enhanced monofocal IOLs provide better intermediate vision with no rings or dysphotopsia

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon